HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Clinical trial NCT05582278 · UNKNOWN

Trial details

NCT number: NCT05582278
Sponsor: Wen Li
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Hepatocellular Carcinoma

Start date: 2021-01-01
Primary completion: 2024-01-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.